146 related articles for article (PubMed ID: 36794283)
1. Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials.
Conaghan PG; Pavelka K; Hsieh SC; Bonnington TL; Kent TC; Marchbank K; Edwards CJ
Rheumatol Adv Pract; 2023; 7(1):rkad017. PubMed ID: 36794283
[TBL] [Abstract][Full Text] [Related]
2. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
[TBL] [Abstract][Full Text] [Related]
3. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
6. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
Mysler E; Tanaka Y; Kavanaugh A; Aletaha D; Taylor PC; Song IH; Shaw T; Song Y; DeMasi R; Ali M; Fleischmann R
Rheumatology (Oxford); 2023 May; 62(5):1804-1813. PubMed ID: 36018230
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y
Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
Peterfy CG; Strand V; Friedman A; Hall S; Mysler E; Durez P; Baraliakos X; Enejosa JV; Shaw T; Li Y; Chen S; Song IH
Rheumatology (Oxford); 2022 Aug; 61(8):3246-3256. PubMed ID: 34897366
[TBL] [Abstract][Full Text] [Related]
9. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
Strand V; Tundia N; Wells A; Buch MH; Radominski SC; Camp HS; Friedman A; Suboticki JL; Dunlap K; Goldschmidt D; Bergman M
Rheumatology (Oxford); 2021 Jul; 60(7):3209-3221. PubMed ID: 33313898
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
[TBL] [Abstract][Full Text] [Related]
11. Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.
Conaghan P; Cohen S; Burmester G; Mysler E; Nash P; Tanaka Y; Rigby W; Patel J; Shaw T; Betts KA; Patel P; Liu J; Sun R; Fleischmann R
Rheumatol Ther; 2022 Feb; 9(1):191-206. PubMed ID: 34816388
[TBL] [Abstract][Full Text] [Related]
12. Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison.
Huizinga T; Choy E; Praestgaard A; van Hoogstraten H; LaFontaine PR; Guyot P; Aletaha D; Müller-Ladner U; Tanaka Y; Curtis JR; Fleischmann R
Rheumatol Ther; 2023 Jun; 10(3):539-550. PubMed ID: 36725768
[TBL] [Abstract][Full Text] [Related]
13. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
Rubbert-Roth A; Kakehasi AM; Takeuchi T; Schmalzing M; Palac H; Coombs D; Liu J; Anyanwu SI; Lippe R; Curtis JR
Rheumatol Ther; 2024 Feb; 11(1):97-112. PubMed ID: 37982966
[TBL] [Abstract][Full Text] [Related]
14. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M
Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649
[TBL] [Abstract][Full Text] [Related]
15. Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.
Kakehasi AM; Radominski SC; Baravalle MD; Palazuelos FCI; Garcia-Garcia C; Arruda MS; Curi M; Liu J; Qiao M; Velez-Sanchez P; Vargas JI
Clin Rheumatol; 2023 May; 42(5):1249-1258. PubMed ID: 36715850
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
17. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
[TBL] [Abstract][Full Text] [Related]
18. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
Nash P; Richette P; Gossec L; Marchesoni A; Ritchlin C; Kato K; McDearmon-Blondell EL; Lesser E; McCaskill R; Feng D; Anderson JK; Ruderman EM
Rheumatology (Oxford); 2022 Aug; 61(8):3257-3268. PubMed ID: 34864911
[TBL] [Abstract][Full Text] [Related]
19. Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study.
Bessette L; Chan J; Chow A; Lisnevskaia L; Richard N; Fournier PA; Liazoghli D; Girard T; Haaland D
Rheumatol Ther; 2024 Jun; 11(3):563-582. PubMed ID: 38467912
[TBL] [Abstract][Full Text] [Related]
20. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
